Asghar Kashif, Loya Asif, Rana Iftikhar Ali, Abu Bakar Muhammad, Farooq Asim, Tahseen Muhammad, Ishaq Muhammad, Rashid Muhammad Usman
Department of Basic Sciences, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan.
Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan.
Asian Pac J Cancer Prev. 2019 Nov 1;20(11):3521-3525. doi: 10.31557/APJCP.2019.20.11.3521.
Tumors use several immunosuppressive mechanisms to evade immune destruction. Cyclooxygenase-2 (COX-2) expression may be a driver of immunosuppression in breast cancer, but the mechanisms involved remain elusive. COX-2 expression induces the expression of indoleamine 2,3 dioxygenase (IDO) in tumor cells. IDO is an immunosuppressive enzyme which is involved in tumor immune escape mechanisms in breast cancer. Our aim was to evaluate the association between COX-2 and IDO expression to find evidence of immunosuppression in Pakistani breast cancer patients.
Immunohistochemical analysis was performed to evaluate the expression of COX-2, IDO, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) on formalin-fixed paraffin-embedded breast cancer tissues of 100 patients. Univariable and multivariable logistic regression model was used to identify the independent risk factors of COX-2.
A total of 100 patients were included with a mean age and standard deviation of 48.28 ± 11.83. A significant association was observed among COX-2, IDO, ER, PR and tumor grade. In multivariable analysis, three variables were identified as significant independent risk factors for high COX-2: IDO expression high; [adjusted odds ratio (AOR) 6.51; 95% confidence interval (CI) (2.00-21.20), p=0.001], ER; [AOR 5.62; 95% CI (1.80-17.84), p=0.002] and age [AOR 1.04; 95% CI (1.00-1.10), p=0.05] respectively.
Our data showed that high IDO expression is associated with high COX-2 expression in Pakistani breast cancer patients. The co-expression of both enzymes may suggest their role in disease pathogenesis. Hence the concurrent targeting of COX-2 and IDO may be a promising therapy for breast cancer.
.
肿瘤利用多种免疫抑制机制来逃避免疫破坏。环氧合酶-2(COX-2)的表达可能是乳腺癌免疫抑制的驱动因素,但其涉及的机制仍不清楚。COX-2的表达可诱导肿瘤细胞中吲哚胺2,3-双加氧酶(IDO)的表达。IDO是一种免疫抑制酶,参与乳腺癌的肿瘤免疫逃逸机制。我们的目的是评估COX-2与IDO表达之间的关联,以寻找巴基斯坦乳腺癌患者免疫抑制的证据。
对100例患者福尔马林固定石蜡包埋的乳腺癌组织进行免疫组织化学分析,以评估COX-2、IDO、雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)的表达。采用单变量和多变量逻辑回归模型确定COX-2的独立危险因素。
共纳入100例患者,平均年龄和标准差分别为48.28±11.83。观察到COX-2、IDO、ER、PR与肿瘤分级之间存在显著关联。在多变量分析中,三个变量被确定为COX-2高表达的显著独立危险因素:IDO表达高;[调整优势比(AOR)6.51;95%置信区间(CI)(2.00-21.20),p=0.001],ER;[AOR 5.62;95%CI(1.80-17.84),p=0.002]和年龄[AOR 1.04;95%CI(1.00-1.10),p=0.05]。
我们的数据表明,在巴基斯坦乳腺癌患者中,IDO高表达与COX-2高表达相关。两种酶的共表达可能提示它们在疾病发病机制中的作用。因此,同时靶向COX-2和IDO可能是一种有前景的乳腺癌治疗方法。